What did @therealchantallu actually say?
After stopping tirzepatide (Zepbound), she regained three of five pounds lost post-discontinuation, noticed her appetite and cravings returned, and attributed ongoing hunger partly to inadequate carbohydrate intake. She also claimed her body composition scale showed she gained two pounds of muscle alongside the three pounds of fat.
To manage the rebound, she described increasing exercise, adding protein via Kodiak Power Cakes and eggs, incorporating some carbohydrates back, and using pistachio butter for caloric density and satiety. The tone was measured and honest, not alarmist. She did not claim the drug cured her obesity or that stopping it was risk-free. That kind of transparency is genuinely rare on weight loss TikTok.
Does the science back this up?
Yes, substantially. Weight regain after stopping GLP-1 receptor agonists is one of the most consistently replicated findings in this drug class. The picture she's describing is textbook discontinuation physiology.
The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) followed participants who discontinued tirzepatide after 36 weeks of treatment. Within 52 weeks of stopping, participants regained roughly two-thirds of their prior weight loss on average. Return of appetite and cravings is the primary driver, exactly what she describes. A 2022 semaglutide withdrawal study (Wilding et al., NEJM) showed nearly identical patterns, with appetite hormones like ghrelin rebounding toward pre-treatment levels within weeks of stopping. Her framing that hunger is "a battle on the weekends" is consistent with what patients in clinical trials report: appetite suppression fades unevenly, often hitting harder in lower-structure environments.
What did they get wrong (or right)?
The muscle gain claim deserves scrutiny. She says her Apple Watch-linked scale shows she gained two pounds of muscle while gaining three pounds of fat. That specific number is probably noise, not signal.
Consumer bioelectrical impedance scales, including those paired with wearables, carry a margin of error of roughly 3-5 pounds for body composition metrics under ideal conditions (Ackland et al., 2012, Sports Medicine). Hydration, time of day, recent food intake, and even skin temperature affect readings significantly. Gaining a measurable two pounds of muscle in a short window while in a caloric surplus is plausible in principle, especially with increased exercise, but you cannot confirm that with a bathroom scale. She may well be building muscle. The exercise increase is real and relevant. But the precise numbers she's citing deserve a healthy dose of skepticism. On the carbohydrate point, she's actually onto something: very low carbohydrate intake can elevate ghrelin and worsen hunger, and reintroducing moderate carbs strategically is not a failure of discipline.
What should you actually know?
GLP-1 and GIP receptor agonists like tirzepatide do not permanently reset appetite regulation. When you stop, the underlying biology that drove weight gain before treatment largely reasserts itself. That is not a character flaw or a failure of effort. It reflects the chronic disease model of obesity.
Research increasingly supports that these medications may need to be continued long-term for sustained effect, similar to how you would manage hypertension or hypothyroidism with ongoing medication. The SURMOUNT-4 data showed that participants who continued tirzepatide maintained their weight loss, while those who switched to placebo did not. Stopping is a legitimate personal and financial decision, but it should be made with clear-eyed expectations about what typically follows. Her response, more exercise, better protein distribution, reintroducing carbs strategically, is genuinely aligned with evidence-based weight maintenance strategies. It does not fully offset discontinuation-related regain for most people, but it is not wrong either.
- Tirzepatide acts on both GIP and GLP-1 receptors, which may explain its stronger weight loss effect compared to semaglutide alone in head-to-head data.
- Protein and fiber intake remain among the strongest dietary levers for hunger management independent of GLP-1 medication status.
- If cost or access drove this discontinuation, that is a systemic problem worth naming: Zepbound runs $1,000 or more per month without insurance coverage.